Home›Companies›Healthcare›Superior Genomics

Superior Genomics, Inc.

Develops blood tests to help diagnose depression and bipolar disorder in patients.

No LinkedIn page we could confirm. Why?
Updated Nov 9, 2026·Latest SEC filing Aug 14, 2026·Suggest an edit

About Superior Genomics

Superior Genomics is a private company based in Norway, Michigan, incorporated in 2023 in Delaware. It has reported $507,500 raised in one offering on Form D since August 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 30, 2026Aug 14, 2026$507,500of $1.5M target14$36,250Simple Agreement for Future Equity (SAFE)Rule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Superior Genomics's Form D filed Aug 14, 2026.

DH
David Van Holla
President and director
JF

Sources

  1. SECSuperior Genomics, Inc. filing history